Arbutus Biopharma Overview
Valuation check: ABUS's ROE is 61.77%, above the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow61.77%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Arbutus Biopharma's return on equity stands at 61.77%. That is above the Healthcare sector average of 22.76%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Arbutus Biopharma sits higher the Healthcare benchmark (22.76%) with a ROE of 61.77%. That is roughly 171.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 61.77% for Arbutus Biopharma means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Arbutus Biopharma's ROE evolved across reporting periods, while the comparison chart places ABUS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Arbutus Biopharma's reading of 61.77% (sector avg 22.76%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
